Collaborations (Details) - Collaborative arrangement - USD ($) $ in Millions |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Genentech, Inc. | ||||
| Collaborative and license agreements | ||||
| Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) | $ 298 | $ 262 | $ 582 | $ 504 |
| Janssen Biotech Inc. | ||||
| Collaborative and license agreements | ||||
| Share of collaboration development costs responsible by Janssen (as a percent) | 60.00% | |||
| Share of collaboration development costs responsible by the entity (as a percent) | 40.00% | |||
| Janssen Biotech Inc. | United States | ||||
| Collaborative and license agreements | ||||
| Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) | 157 | 253 | $ 310 | 500 |
| Janssen Biotech Inc. | International | ||||
| Collaborative and license agreements | ||||
| International - AbbVie's share of profits (included in net revenues) | $ 195 | $ 211 | $ 419 | $ 420 |